SK Biopharmaceuticals Partners with Eurofarma for AI-Driven Epilepsy Care Solution
In a significant move for digital healthcare, SK Biopharmaceuticals has teamed up with Eurofarma to launch Mentis Care, a new joint venture aimed at revolutionizing the management of epilepsy using artificial intelligence. The collaborative effort focuses on developing an integrated ecosystem that will leverage advanced AI technologies to improve patient outcomes in epilepsy care.
The inauguration of Mentis Care took place in Toronto, Canada, on October 20, 2025, and symbolizes SK Biopharmaceuticals' commitment to advancing beyond pharmaceutical innovation into the digital health arena. The new venture aims to commercialize an AI-based platform that integrates real-time seizure detection and predictive analytics to better support patients and healthcare providers.
SK Biopharmaceuticals has been at the forefront of AI technology in neurology since 2018, honing expertise in electroencephalography (EEG) and wearable devices that monitor seizure activity. The company's rich history in the field serves as a solid foundation for Mentis Care, which is set to deliver a pioneering digital platform combining clinical decision support tools with seizure prediction algorithms, ultimately creating personalized care for epilepsy patients.
Located in the MaRS Discovery District—one of North America's leading hubs for innovation—Mentis Care is uniquely positioned to foster collaboration between academia, industry, and patients. The organization plans to expand its workforce in Toronto and engage in clinical validations to ensure its AI algorithms are robust and effective.
Eurofarma, a major player in the Latin American healthcare market, will contribute its strategic expertise and knowledge in AI data learning to the venture. This partnership builds on a successful collaboration dating back to 2022, during which the two companies worked together to develop and market cenobamate, an anti-seizure medication. This new chapter in their alliance emphasizes the importance of integrating digital healthcare innovations with existing medication strategies.
Hassan Kotob, the newly appointed CEO of Mentis Care, brings considerable experience in leading healthcare technology initiatives. His role will involve spearheading the development of a unique AI platform aimed at enhancing brain health by providing real-time monitoring and predictions related to seizures. “Our mission is to empower patients with epilepsy to lead safer, more independent lives through technology-driven solutions,” remarked Kotob.
The collaborative approach of SK Biopharmaceuticals and Eurofarma reflects a future-oriented vision for healthcare. With Eurofarma's extensive experience in CNS treatments and SK's innovative capabilities, Mentis Care is positioned to set a new standard in epilepsy management on a global scale.
As SK Biopharmaceuticals continues to explore new horizons in digital health, it aims to harness the power of AI and clinical data in crafting more effective and personalized treatments for epilepsy patients. This venture not only promises to enhance patient care but also exemplifies a growing trend in the healthcare industry towards the integration of new technologies to improve health outcomes.
In addition to improving seizure management, the initiatives from Mentis Care could help address broader challenges faced by epilepsy patients and contribute to significant advancements in the understanding and treatment of neurological disorders. The ongoing collaboration between SK Biopharmaceuticals and Eurofarma represents a significant milestone in the evolution of healthcare technology, emphasizing the importance of partnerships in delivering sustainable and effective healthcare solutions for patients worldwide.
As the landscape of healthcare continues to evolve with technology, projects like Mentis Care pave the way for innovative transformations in patient care and the overall management of chronic diseases. The integration of AI into epilepsy management could revolutionize how healthcare providers monitor and address the needs of their patients, bringing hope and improved quality of life to millions living with epilepsy.
The inauguration of Mentis Care took place in Toronto, Canada, on October 20, 2025, and symbolizes SK Biopharmaceuticals' commitment to advancing beyond pharmaceutical innovation into the digital health arena. The new venture aims to commercialize an AI-based platform that integrates real-time seizure detection and predictive analytics to better support patients and healthcare providers.
SK Biopharmaceuticals has been at the forefront of AI technology in neurology since 2018, honing expertise in electroencephalography (EEG) and wearable devices that monitor seizure activity. The company's rich history in the field serves as a solid foundation for Mentis Care, which is set to deliver a pioneering digital platform combining clinical decision support tools with seizure prediction algorithms, ultimately creating personalized care for epilepsy patients.
Located in the MaRS Discovery District—one of North America's leading hubs for innovation—Mentis Care is uniquely positioned to foster collaboration between academia, industry, and patients. The organization plans to expand its workforce in Toronto and engage in clinical validations to ensure its AI algorithms are robust and effective.
Eurofarma, a major player in the Latin American healthcare market, will contribute its strategic expertise and knowledge in AI data learning to the venture. This partnership builds on a successful collaboration dating back to 2022, during which the two companies worked together to develop and market cenobamate, an anti-seizure medication. This new chapter in their alliance emphasizes the importance of integrating digital healthcare innovations with existing medication strategies.
Hassan Kotob, the newly appointed CEO of Mentis Care, brings considerable experience in leading healthcare technology initiatives. His role will involve spearheading the development of a unique AI platform aimed at enhancing brain health by providing real-time monitoring and predictions related to seizures. “Our mission is to empower patients with epilepsy to lead safer, more independent lives through technology-driven solutions,” remarked Kotob.
The collaborative approach of SK Biopharmaceuticals and Eurofarma reflects a future-oriented vision for healthcare. With Eurofarma's extensive experience in CNS treatments and SK's innovative capabilities, Mentis Care is positioned to set a new standard in epilepsy management on a global scale.
As SK Biopharmaceuticals continues to explore new horizons in digital health, it aims to harness the power of AI and clinical data in crafting more effective and personalized treatments for epilepsy patients. This venture not only promises to enhance patient care but also exemplifies a growing trend in the healthcare industry towards the integration of new technologies to improve health outcomes.
In addition to improving seizure management, the initiatives from Mentis Care could help address broader challenges faced by epilepsy patients and contribute to significant advancements in the understanding and treatment of neurological disorders. The ongoing collaboration between SK Biopharmaceuticals and Eurofarma represents a significant milestone in the evolution of healthcare technology, emphasizing the importance of partnerships in delivering sustainable and effective healthcare solutions for patients worldwide.
As the landscape of healthcare continues to evolve with technology, projects like Mentis Care pave the way for innovative transformations in patient care and the overall management of chronic diseases. The integration of AI into epilepsy management could revolutionize how healthcare providers monitor and address the needs of their patients, bringing hope and improved quality of life to millions living with epilepsy.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.